Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3738351 | 0.88 | HSD17B10 (0.64) | HSD17B10CYP11B1CYP11B2KDM4EABL1 | |
| SCHEMBL9890648 | 0.87 | HSD17B10 (0.62) | HSD17B10KDM4EABL1POLBMAPT | |
| SCHEMBL3737508 | 0.85 | CYP11B2 (0.55) | HSD17B10CYP11B1CYP11B2KDM4ETHRA | |
| SCHEMBL3735319 | 0.84 | HSD17B10 (0.59) | HSD17B10CYP11B1CYP11B2KDM4EABL1 | |
| SCHEMBL3736235 | 0.83 | HSD17B10 (0.57) | HSD17B10KDM4EABL1POLBMAPT | |
| SCHEMBL5235960 | 0.80 | HSD17B10 (0.54) | HSD17B10KDM4EPTGS1SMN1; SMN2LCK | |
| SCHEMBL11889771 | 0.78 | HSD17B10 (0.55) | HSD17B10KDM4EABL1SMN1; SMN2MMP2 | |
| SCHEMBL3741185 | 0.78 | PTGDR2 (0.49) | CYP11B1CYP11B2AKR1C3AKR1C2CYP46A1 | |
| SCHEMBL3736875 | 0.78 | KEAP1 (0.47) | MAPTCYP46A1THRATHRBCDC7 | |
| SCHEMBL3749551 | 0.77 | HSD17B10 (0.54) | HSD17B10KDM4EPTGS1AKR1C3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255173-A1 | Novel Specific Caspase-10 Inhibitors | MERCK PATENT GESELLSCHAFT (DE) | 2008-10-16 | — | — | US | claimed |
| EP-1817031-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | Merck Patent GmbH (DE) | 2007-08-15 | — | — | EP | claimed |
| WO-2006058592-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | MERCK PATENT GMBH (DE) | 2006-06-08 | — | — | WO | claimed |
| US-7829721-B2 | Specific caspase-10 inhibitors | MERCK PATENT GMBH (DE) | 2010-11-09 | — | — | US | disclosed |
| US-20080255173-A1 | Novel Specific Caspase-10 Inhibitors | MERCK PATENT GESELLSCHAFT (DE) | 2008-10-16 | — | — | US | disclosed |
| EP-1817031-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | Merck Patent GmbH (DE) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006058592-A1 | NOVEL SPECIFIC CASPASE-10 INHIBITORS | MERCK PATENT GMBH (DE) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255173-A1 | Novel Specific Caspase-10 Inhibitors | CASP10, CASP1, CASP5 | HSD17B10 120/4885CYP11B1 1685/4885CYP11B2 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.